

SUPPLEMENTARY DATA

Table 1 of the supplementary data

Change in New York Heart Association (NYHA) functional class I-II vs III-IV from baseline to 30-day follow -up

Group 1 – Improvement NYHA III-IV → NYHA I-II	1798 patients (52%)
Group 2 – No change of NYHA class I-II → I-II	1456 patients (42%)
Group 3 – No change of NYHA class III-IV → III-IV	160 patients (5%)
Group 4 – Worsening of NYHA class I-II → III-IV	48 patients (1%)

Table 2 of the supplementary data

Results of the univariate logistic regression analysis. Variables with an association ($P < .10$) were included in the multivariate logistic regression analysis

Covariate	OR (95%CI)	P
<i>Age, y</i>	1.00 (0.98-1.0)	.62
<i>Female sex</i>	0.86 (0.65-1.14)	.31
<i>NYHA III-IV, baseline</i>	2.70 (1.94-3.75)	< .01
<i>Coronary artery disease</i>	1.21 (0.91-1.60)	.20
<i>Atrial fibrillation</i>	1.49 (1.12-1.99)	< .01
<i>Previous pacemaker</i>	1.46 (0.98-2.16)	< .01
<i>eGFR < 60 mL/min/1.73 m²</i>	1.08 (0.82-1.44)	.58
<i>NT pro-BNP</i>	1.00 (0.99-1.00)	.17
<i>COPD</i>	1.80 (1.35-2.41)	< .01
<i>Previous stroke</i>	1.35 (0.87-2.01)	.18
<i>Baseline reduced LVEF</i>	1.69 (1.19-2.38)	< .01

<i>Baseline aortic valve area</i>	1.00 (0.89-1.12)	.96
<i>Baseline peak aortic gradient</i>	0.98 (0.98-0.99)	< .01
<i>Baseline mean aortic gradient</i>	0.98 (0.97-0.99)	< .01
<i>Self-expandable valve</i>	0.90 (0.67-1.22)	.50
<i>Transfemoral approach</i>	0.44 (0.30-0.63)	< .01
<i>TAVR in SAVR procedure</i>	0.57 (0.28-1.17)	.13
<i>Major vascular complication</i>	0.82 (0.39-1.68)	.58
<i>Major bleeding</i>	0.78 (0.31-1.93)	.59
<i>New-onset atrial fibrillation</i>	1.21 (0.71-2.10)	.48
<i>New-onset left bundle branch block</i>	1.23 (0.77-1.97)	.39
<i>Post-TAVR pacemaker</i>	1.20 (0.84-1.69)	.31
<i>Post-TAVR reduced LVEF</i>	1.68 (1.16-2.45)	< .01
<i>Severe PPM (VARC-3)</i>	1.39 (0.41-4.63)	.60
<i>Post-TAVR peak aortic gradient</i>	0.98 (0.96-1.00)	.04
<i>Post-TAVR mean gradient</i>	1.00 (0.96-1.03)	.80
<i>Post-TAVR severe mitral regurgitation</i>	3.03 (2.07-4.43)	< .01
<i>Post-TAVR > mild aortic regurgitation</i>	1.40 (0.81-2.42)	.23
<i>Pulmonary hypertension</i>		
Moderate (PASP 31-55 mmHg)	1.67 (1.05-2.65)	.03
Severe (PASP > 55 mmHg)	2.91 (1.55-5.46)	< .01

COPD, chronic pulmonary obstructive disease; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; OR, odds ratio; PASP, pulmonary artery systolic pressure; PPM, prosthesis-patient mismatch; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement.

Table 3 of the supplementary data

Results of the univariate and multivariate logistic regression analyses excluding patients with COPD.

Variables with an association ($P < .10$) were included in the multivariate logistic regression analysis.

Covariate	Univariate regression		Multivariate regression	
	OR (95%CI)	P	OR (95%CI)	P
<i>Age, y</i>	1.01 (0.98-1.04)	.47		
<i>Female sex</i>	0.97 (0.68-1.39)	.88		
<i>NYHA III-IV, baseline</i>	2.58 (1.72-3.86)	< .01	1.55 (0.84-2.85)	.16
<i>Coronary artery disease</i>	1.27 (0.89-1.81)	.19		
<i>Atrial fibrillation</i>	1.71 (1.19-2.45)	< .01	1.68 (0.96-2.91)	.07
<i>Previous pacemaker</i>	1.27 (0.76-2.12)	.36		
<i>eGFR < 60 mL/min/1.73 m²</i>	1.25 (0.87-1.80)	.22		
<i>NT pro-BNP</i>	1.00 (0.99-1.00)	.60		
<i>Previous stroke</i>	1.01 (0.55-1.87)	.96		
<i>Baseline reduced LVEF</i>	1.94 (1.27-2.96)	< .01	1.02 (0.36-2.89)	.96
<i>Baseline aortic valve area</i>	1.00 (0.91-1.11)	.95		
<i>Baseline peak aortic gradient</i>	0.98 (0.97-0.99)	< .01	0.99 (0.96-1.01)	.29
<i>Baseline mean aortic gradient</i>	0.98 (0.96-0.99)	< .01	0.99 (0.96-1.03)	.67
<i>Self-expandable valve</i>	1.06 (0.74-1.54)	.74		
<i>Transfemoral approach</i>	0.46 (0.28-0.74)	.01	0.80 (0.37-1.74)	.57
<i>TAVR in SAVR procedure</i>	0.56 (0.22-1.38)	.21		
<i>Major vascular complication</i>	1.01 (0.44-2.34)	.98		
<i>Major bleeding</i>	0.76 (0.24-2.44)	.64		
<i>New-onset atrial fibrillation</i>	1.72 (0.92-3.19)	.09	3.08 (1.38-6.87)	< .01

<i>New-onset left bundle branch block</i>	1.14 (0.61-2.14)	.68		
<i>Post-TAVR pacemaker</i>	1.16 (0.74-1.80)	.52		
<i>Post-TAVR reduced LVEF</i>	1.94 (1.23-3.08)	< .01	1.46 (0.51-4.21)	.48
<i>Severe PPM (VARC-3)</i>	1.72 (0.39-7.59)	.47		
<i>Post-TAVR peak aortic gradient</i>	0.98 (0.95-0.99)	.04	0.98 (0.95-1.02)	.35
<i>Post-TAVR mean gradient</i>	0.99 (0.95-1.02)	.56		
<i>Post-TAVR severe MR</i>	3.08 (1.94-4.88)	< .01	2.24 (1.22-4.10)	< .01
<i>Post-TAVR > mild AR</i>	1.93 (1.05-3.52)	.03	1.22 (0.54-2.76)	.64
<i>Pulmonary hypertension</i>				
Moderate (PASP 31-55 mmHg)	1.72 (0.96-3.01)	.07	1.36 (0.67-2.75)	.39
Severe (PASP > 55 mmHg)	3.22 (1.46-7.12)	< .01	1.41 (0.48-4.11)	.53

COPD, chronic pulmonary obstructive disease; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; PASP, pulmonary artery systolic pressure; PPM, prosthesis-patient mismatch; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement.